Therapeutic Potential of Ethyl Acetate Fraction of Methanolic Extract of Camellia Sinensis (Green Tea) in Diabetes and Hyperlipidaemia Management in Streptozotocin induced Diabetic Male Albino Rat

Abstract

This study investigates the therapeutic potential of the ethyl acetate fraction derived from the methanolic extract of Camellia sinensis (green tea) in managing diabetes and hyperlipidemia using a streptozotocin-induced diabetic male albino rat model. Diabetes and hyperlipidemia pose significant health challenges globally, with limited effective treatments available. Green tea, known for its rich polyphenolic content and antioxidant properties, has shown promising therapeutic effects in various metabolic disorders. In this research, streptozotocin-induced diabetic male albino rats were treated with the ethyl acetate fraction of green tea extract. Parameters such as blood glucose levels, lipid profile, and antioxidant enzymes activity were assessed. The findings reveal that treatment with the ethyl acetate fraction of methanolic extract of Camellia sinensis (green tea) resulted in significant (p<0.05) reductions in blood glucose levels and improvement in lipid profile parameters compared to the diabetic control group. Furthermore, histopathological examination indicated amelioration of pancreatic tissue damage in treated rats. These results suggest that the ethyl acetate fraction of green tea extract holds promise as a therapeutic agent for managing diabetes and hyperlipidemia. Further research elucidating the underlying mechanisms and clinical trials are warranted to validate its efficacy and safety for human use.